Literature DB >> 27053857

Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma.

Jian-Feng Yang1, Zhen-Hua Zhao1, Yu Zhang1, Li Zhao1, Li-Ming Yang1, Min-Ming Zhang1, Bo-Yin Wang1, Ting Wang1, Bao-Chun Lu1.   

Abstract

AIM: To investigate the feasibility of a dual-input two-compartment tracer kinetic model for evaluating tumorous microvascular properties in advanced hepatocellular carcinoma (HCC).
METHODS: From January 2014 to April 2015, we prospectively measured and analyzed pharmacokinetic parameters [transfer constant (Ktrans), plasma flow (Fp), permeability surface area product (PS), efflux rate constant (kep), extravascular extracellular space volume ratio (ve), blood plasma volume ratio (vp), and hepatic perfusion index (HPI)] using dual-input two-compartment tracer kinetic models [a dual-input extended Tofts model and a dual-input 2-compartment exchange model (2CXM)] in 28 consecutive HCC patients. A well-known consensus that HCC is a hypervascular tumor supplied by the hepatic artery and the portal vein was used as a reference standard. A paired Student's t-test and a nonparametric paired Wilcoxon rank sum test were used to compare the equivalent pharmacokinetic parameters derived from the two models, and Pearson correlation analysis was also applied to observe the correlations among all equivalent parameters. The tumor size and pharmacokinetic parameters were tested by Pearson correlation analysis, while correlations among stage, tumor size and all pharmacokinetic parameters were assessed by Spearman correlation analysis.
RESULTS: The Fp value was greater than the PS value (FP = 1.07 mL/mL per minute, PS = 0.19 mL/mL per minute) in the dual-input 2CXM; HPI was 0.66 and 0.63 in the dual-input extended Tofts model and the dual-input 2CXM, respectively. There were no significant differences in the kep, vp, or HPI between the dual-input extended Tofts model and the dual-input 2CXM (P = 0.524, 0.569, and 0.622, respectively). All equivalent pharmacokinetic parameters, except for ve, were correlated in the two dual-input two-compartment pharmacokinetic models; both Fp and PS in the dual-input 2CXM were correlated with Ktrans derived from the dual-input extended Tofts model (P = 0.002, r = 0.566; P = 0.002, r = 0.570); kep, vp, and HPI between the two kinetic models were positively correlated (P = 0.001, r = 0.594; P = 0.0001, r = 0.686; P = 0.04, r = 0.391, respectively). In the dual input extended Tofts model, ve was significantly less than that in the dual input 2CXM (P = 0.004), and no significant correlation was seen between the two tracer kinetic models (P = 0.156, r = 0.276). Neither tumor size nor tumor stage was significantly correlated with any of the pharmacokinetic parameters obtained from the two models (P > 0.05).
CONCLUSION: A dual-input two-compartment pharmacokinetic model (a dual-input extended Tofts model and a dual-input 2CXM) can be used in assessing the microvascular physiopathological properties before the treatment of advanced HCC. The dual-input extended Tofts model may be more stable in measuring the ve; however, the dual-input 2CXM may be more detailed and accurate in measuring microvascular permeability.

Entities:  

Keywords:  Dynamic contrast-enhanced magnetic resonance imaging; Hepatocellular carcinoma; Pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 27053857      PMCID: PMC4814651          DOI: 10.3748/wjg.v22.i13.3652

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability.

Authors:  S P Sourbron; D L Buckley
Journal:  Phys Med Biol       Date:  2011-12-15       Impact factor: 3.609

Review 3.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

Review 4.  Models and methods for analyzing DCE-MRI: a review.

Authors:  Fahmi Khalifa; Ahmed Soliman; Ayman El-Baz; Mohamed Abou El-Ghar; Tarek El-Diasty; Georgy Gimel'farb; Rosemary Ouseph; Amy C Dwyer
Journal:  Med Phys       Date:  2014-12       Impact factor: 4.071

Review 5.  Perfusion magnetic resonance imaging of the liver.

Authors:  Choon Hua Thng; Tong San Koh; David J Collins; Dow Mu Koh
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

6.  Transvascular and interstitial transport in rat hepatocellular carcinomas: dynamic contrast-enhanced MRI assessment with low- and high-molecular weight agents.

Authors:  Nicolas Michoux; Laurent Huwart; Jorge Abarca-Quinones; Mylène Dorvillius; Laurence Annet; Frank Peeters; Bernard E Van Beers
Journal:  J Magn Reson Imaging       Date:  2008-10       Impact factor: 4.813

7.  Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material.

Authors:  Makiko Hayashi; Osamu Matsui; Kazuhiko Ueda; Yasuhiro Kawamori; Toshifumi Gabata; Masumi Kadoya
Journal:  Radiology       Date:  2002-10       Impact factor: 11.105

Review 8.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

9.  Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.

Authors:  S De Bruyne; N Van Damme; P Smeets; L Ferdinande; W Ceelen; J Mertens; C Van de Wiele; R Troisi; L Libbrecht; S Laurent; K Geboes; M Peeters
Journal:  Br J Cancer       Date:  2012-05-17       Impact factor: 7.640

10.  Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.

Authors:  Dushyant V Sahani; Tao Jiang; Koichi Hayano; Dan G Duda; Onofrio A Catalano; Marek Ancukiewicz; Rakesh K Jain; Andrew X Zhu
Journal:  J Hematol Oncol       Date:  2013-07-10       Impact factor: 17.388

View more
  9 in total

1.  Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer.

Authors:  Rui Zhang; Zhi-Yu Wang; Yue-Hua Li; Yao-Hong Lu; Shuai Wang; Wen-Xi Yu; Hui Zhao
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  DWI and DCE-MRI approaches for differentiating reversibly electroporated penumbra from irreversibly electroporated ablation zones in a rabbit liver model.

Authors:  Anna J Shangguan; Chong Sun; Bin Wang; Liang Pan; Quanhong Ma; Su Hu; Jia Yang; Aydin Eresen; Yuri Velichko; Vahid Yaghmai; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

3.  Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study.

Authors:  Marta Campos; Isabel Candelária; Nickolas Papanikolaou; Adélia Simão; Carlos Ferreira; Georgios C Manikis; Filipe Caseiro-Alves
Journal:  GE Port J Gastroenterol       Date:  2019-02-18

4.  Free-Breathing 3D Liver Perfusion Quantification Using a Dual-Input Two-Compartment Model.

Authors:  Satyam Ghodasara; Shivani Pahwa; Sara Dastmalchian; Vikas Gulani; Yong Chen
Journal:  Sci Rep       Date:  2017-12-13       Impact factor: 4.379

5.  Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment.

Authors:  Hiroyuki Fukuda; Kazushi Numata; Koji Hara; Akito Nozaki; Masaaki Kondo; Makoto Chuma; Masayuki Nakano; Akinori Nozawa; Shin Maeda; Katsuaki Tanaka
Journal:  J Cancer       Date:  2018-06-14       Impact factor: 4.207

6.  3D nonrigid motion correction for quantitative assessment of hepatic lesions in DCE-MRI.

Authors:  Matteo Ippoliti; Mathias Lukas; Winfried Brenner; Tobias Schaeffter; Marcus R Makowski; Christoph Kolbitsch
Journal:  Magn Reson Med       Date:  2019-06-22       Impact factor: 4.668

7.  Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Evaluation of the Cell Density and Angiogenesis of Cirrhosis-Related Nodules in an Experimental Rat Model: Comparison and Correlation With Dynamic Contrast-Enhanced MRI.

Authors:  Jiawen Luo; Kunpeng Zhou; Bin Zhang; Ning Luo; Jie Bian
Journal:  J Magn Reson Imaging       Date:  2019-06-27       Impact factor: 4.813

8.  Correlation of radiomic features on dynamic contrast-enhanced magnetic resonance with microvessel density in hepatocellular carcinoma based on different models.

Authors:  Hongwei Liang; Chunhong Hu; Jian Lu; Tao Zhang; Jifeng Jiang; Ding Ding; Sheng Du; Shaofeng Duan
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 9.  Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Andrea Belli; Carmen Cutolo; Silvia Pradella; Giulia Grazzini; Michelearcangelo La Porta; Maria Chiara Brunese; Federica De Muzio; Alessandro Ottaiano; Antonio Avallone; Francesco Izzo; Antonella Petrillo
Journal:  Infect Agent Cancer       Date:  2021-07-19       Impact factor: 2.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.